<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159599</url>
  </required_header>
  <id_info>
    <org_study_id>GESIDA 8014</org_study_id>
    <secondary_id>2014-000515-14</secondary_id>
    <nct_id>NCT02159599</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject</brief_title>
  <acronym>DUAL</acronym>
  <official_title>An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppressed Plasma Viremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion SEIMC-GESIDA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion SEIMC-GESIDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label randomized clinial trial to evaluate the treatment with
      darunavir/ritonavir (800mg/100mg) plus lamivudine (300 mg) once daily versus continuing with
      darunavir/ritonavir (800mg/100mg) once daily plus tenofovir/emtricitabine (300mg/200mg) or
      abacavir/lamivudine (600mg/300mg) in HIV infected subject with suppressed plasma viremia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with undetectable viral load</measure>
    <time_frame>week 48</time_frame>
    <description>Undetectable viral load &lt;50 copies/ml according to the FDA snapshot algorithm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable viral load</measure>
    <time_frame>Week 24</time_frame>
    <description>Undetectable viral load &lt; 50 copies/ml according to the FDA snapshot algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with viral load &lt; 200 copies/ml</measure>
    <time_frame>week 48</time_frame>
    <description>Proportion of patients with viral load &lt; 200 copies/ml according to FDA snapshot algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who present viral load ≥ 50 copies /ml one time</measure>
    <time_frame>From basal visit until week 48 visit</time_frame>
    <description>Viral load ≥ 50 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who present viral load ≥ 50 copies /ml more tan two times</measure>
    <time_frame>From basal visit until week 48 visit</time_frame>
    <description>Viral load ≥ 50 copies /ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who maintained viral load &lt; 50 copies/ml in all determinations</measure>
    <time_frame>week 48</time_frame>
    <description>Viral load &lt; 50 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median of change cells CD4/µl count from basal to week 48</measure>
    <time_frame>week 48</time_frame>
    <description>CD4/µl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median of change in triglycerides , LDL-cholesterol, HDL-cholesterol and total cholesterol from basal to week 48</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>week 48</time_frame>
    <description>Change in glomerular filtration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of patients with renal tubular dysfunction</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of genotypic resistance mutations</measure>
    <time_frame>Week 48</time_frame>
    <description>Mutations in patients viral failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in proportion of genotypic resistance mutations</measure>
    <time_frame>week 48</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Darunavir/Ritonavir + 2 nucleos(t)idos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir/ritonavir + Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir/Ritonavir</intervention_name>
    <description>Darunavir/ritonavir (800/100 mg): QD (quaque die )</description>
    <arm_group_label>Darunavir/Ritonavir + 2 nucleos(t)idos</arm_group_label>
    <arm_group_label>Darunavir/ritonavir + Lamivudine</arm_group_label>
    <other_name>Prezista/Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine (300mg) : QD</description>
    <arm_group_label>Darunavir/ritonavir + Lamivudine</arm_group_label>
    <other_name>Epivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir or abacavir/lamivudine</intervention_name>
    <description>Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD</description>
    <arm_group_label>Darunavir/Ritonavir + 2 nucleos(t)idos</arm_group_label>
    <other_name>Truvada or Kivexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acceptance to participate in the study, signing the informed consent document before
             conducting any study procedures.

          2. Patient with HIV infection older than 18 years.

          3. Treatment with darunavir/ritonavir once a day and tenofovir/emtricitabine or
             abacavir/lamivudine during at least 4 weeks at the moment of the screening

          4. Plasma HIV RNA levels below 50 copies / ml for at least 6 months (two separate
             measurements at least 6 months with viremia &lt;50 copies / ml between both).

          5. HbsAg negative

        Exclusion Criteria:

          1. Pregnant or breastfeeding woman

          2. Evidence of Lamivudine resistance (any previous genotype with mutation M184V/I or
             K65R) and/or to darunavir (population genotype show any of the following mutations:
             V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, T74P, L76V, I84V, L89V).

          3. History of virology failure (two consecutive viral loads above 200 copies/ml) while
             the patient was receiving a regimen with lamivudine or emtricitabine, with the
             following exceptions:

               -  Do not consider an exclusion criterion if the genotype performed at the time of
                  failure does not demonstrate resistance to lamivudine and darunavir (see criteria
                  2).

               -  Do not consider an exclusion criteria in the absence of genotype if after the
                  episode turns to maintain a viral load &lt;50 copies / ml with a treatment composed
                  of lamivudine or emtricitabine + a nucleoside + a non-nucleoside.

          4. History of abandonment of treatment including lamivudine or emtricitabine, with the
             following exception:

             - Viral load prior to abandonment was &lt;50 copies / ml and subsequent reintroduction of
             the same treatment or another treatment consisting of lamivudine or emtricitabine + a
             nucleoside + a non-nucleoside returns to maintain viral load below 50 copies / ml .

          5. Previous treatment with bitherapy or monotherapy with lamivudine or emtricitabine

          6. Previous treatment with bitherapy or monotherapy with a regimen with a protease
             inhibitor that is terminated by viral rebound, when the absence of a genotypic
             resistance test available after viral rebound allow discard the resistance mutations
             either drug used.

          7. The use of concomitant medication not permitted

          8. Presence of active acute infection, including opportunist infection that a judge of
             investigator that can difficult the participation in the trial

          9. Any laboratory results of the following: hemoglobin&lt;8,0 g/dl; neutrophils &lt;750
             cells/µl; platelets &lt;50.000 cell/µl; creatinine ≥ 1,5 ULN (upper limit of normal)

         10. Any clinical or analytic event that, in the investigator judgment, condition the
             patient safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose R Arribas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federico Pulido, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esteban Ribera, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Huelva</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

